Robeco Institutional Asset Management B.V. Trims Stock Holdings in Illumina, Inc. $ILMN

Key Points

• Robeco trimmed its stake in Illumina by 9.9% in Q4, selling 7,779 shares and leaving it with 70,997 shares valued at about $9.31 million.
• Illumina beat quarterly estimates (EPS $1.35 vs. $1.26 est.; revenue $1.16B vs. $1.10B) and set FY2026 guidance of 5.050–5.200 EPS.
• Insider and market positioning: SVP Patricia Leckman sold 2,370 shares (a 12.68% reduction), institutional ownership stands at 89.42%, and analysts carry a consensus "Hold" rating with a $129.69 target despite some firms raising targets (e.g., Guggenheim to $170).

Robeco Institutional Asset Management B.V. trimmed its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 70,997 shares of the life sciences company's stock after selling 7,779 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Illumina were worth $9,312,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its holdings in Illumina by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company's stock worth $79,081,000 after acquiring an additional 124,246 shares in the last quarter. Generali Asset Management SPA SGR increased its position in shares of Illumina by 51.6% during the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company's stock valued at $2,113,000 after acquiring an additional 7,574 shares in the last quarter. Aaron Wealth Advisors LLC increased its position in shares of Illumina by 342.6% during the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company's stock valued at $995,000 after acquiring an additional 8,109 shares in the last quarter. Elo Mutual Pension Insurance Co bought a new stake in shares of Illumina during the third quarter valued at approximately $2,319,000. Finally, Douglas Lane & Associates LLC increased its position in shares of Illumina by 6.6% during the third quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company's stock valued at $29,214,000 after acquiring an additional 18,914 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company's stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.60% of the company's stock.

Illumina Stock Up 1.5%

ILMN stock opened at $132.26 on Thursday. Illumina, Inc. has a fifty-two week low of $69.83 and a fifty-two week high of $155.53. The business's 50-day moving average is $123.53 and its two-hundred day moving average is $124.23. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a market cap of $20.09 billion, a price-to-earnings ratio of 24.27, a P/E/G ratio of 2.50 and a beta of 1.49.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts' consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the company earned $0.95 earnings per share. Illumina's revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ILMN. Guggenheim raised their price target on shares of Illumina from $144.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, January 26th. UBS Group reissued a "neutral" rating and set a $135.00 price target on shares of Illumina in a research report on Friday, February 6th. Wall Street Zen raised Illumina from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Illumina in a report on Monday, December 29th. Finally, Zacks Research downgraded Illumina from a "strong-buy" rating to a "hold" rating in a report on Wednesday, December 31st. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $129.69.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.